Double-blind, Randomized, Vehicle-controlled Proof of Concept Study on the Efficacy, Safety, Local Tolerability, PK and Pharmacodynamics of Multiple Topical Administrations of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas.
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2015
At a glance
- Drugs Sonidegib (Primary)
- Indications Basal cell cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 29 Oct 2015 Time frame for primary endpoint has changed from 12 weeks to day 43 according to ClinicalTrials.gov.
- 29 Oct 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.